Zdanowicz Michał, Chroboczek Jadwiga
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland; and Therex, TIMC-IMAG, CNRS UMR 5525, UJF, Domaine de la Merci, 38700 La Tronche, France.
Acta Biochim Pol. 2016;63(3):469-73. doi: 10.18388/abp.2016_1275. Epub 2016 Jul 30.
Virus-like particles (VLPs) assemble spontaneously during the viral cycle or in heterologous systems during expression of viral structural protein. Depending on the complexity of the VLPs, they can be obtained by expression in prokaryotic or eukaryotic expression system from the suitable recombinant vectors, or formed in cell-free conditions. Moreover, they can be built from proteins of a single virus, or can present the proteins or peptides derived from a virus or cell on a platform derived from any other single virus, thus forming chimeric VLPs. VLPs are best known for their immunogenic properties, but the versatility of VLPs allows a wide variety of applications. They are lately in the centre of investigations in vaccinology, drug delivery and gene therapy. This review focuses on utilization of VLPs for drug delivery.
病毒样颗粒（VLPs）在病毒周期中自发组装，或在病毒结构蛋白表达过程中于异源系统中组装。根据VLPs的复杂性，它们可以通过在原核或真核表达系统中从合适的重组载体表达获得，或在无细胞条件下形成。此外，它们可以由单一病毒的蛋白质构建而成，或者可以在源自任何其他单一病毒的平台上呈现源自病毒或细胞的蛋白质或肽，从而形成嵌合VLPs。VLPs以其免疫原性而闻名，但VLPs的多功能性使其具有广泛的应用。它们最近成为疫苗学、药物递送和基因治疗研究的核心。本综述重点关注VLPs在药物递送方面的应用。
